Global Testosterone Cypionate

Testosterone Cypionate Comprehensive Study by Application (Primary Hypogonadism, Hypogonadotropic Hypogonadism, Late-Onset Hypogonadism), Route of Administration (Injectable, Parenteral), Active Ingredient (Testosterone, Methyl Testosterone, Testosterone Undecanoate, Testosterone Enanthate, Testosterone Cypionate), Dose (200 mg/mL, 100 mg/mL) Players and Region - Global Market Outlook to 2024

Testosterone Cypionate Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Testosterone Cypionate Market Scope
Testosterone Cypionate is utilized for Symptoms of Low Testosterone in Adult Men. Testosterone Cypionate helps in improving the patient's condition by operating the functions including Supplementing or replacing the testosterone that naturally occurs in the body. In the United Kingdom, The Men’s Health Clinic is a first clinic that gets approval for the importation of the Testosterone Cypionate. The major issue which is hindering in the growth of the market is rising consumer concern towards side effects of this therapy, the companies are managing these side effects by offering simple dose alteration of injection. Basically, it is a Testosterone cypionate is defined as a white or creamy white crystalline powder that considered as odorless.

The market study is being classified, by Application (Primary Hypogonadism, Hypogonadotropic Hypogonadism and Late-Onset Hypogonadism) and major geographies with country level break-up.

The global testosterone cypionate market is a highly competitive market in the healthcare industry and it is having leading players in the market. In concern of the market share, some of the key players highly dominating in pharma industry across the global market. These leading players are focusing on strategic initiatives to enhance the market share and explore their profitability. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Testosterone Cypionate market throughout the predicted period.

Pfizer (United States), Cipla (India), Sun Pharmaceutical (India), Teva (Israel), Perrigo (Ireland), Hikma Pharmaceuticals (United Kingdom), Actiza Pharmaceutical Private Limited (India), Abbvie, Inc. (United States), McKesson Corporation (United States) and Perrigo Company plc (Ireland) are some of the key players profiled in the study.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Testosterone Cypionate market by Type, Application and Region.

On the basis of geography, the market of Testosterone Cypionate has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Market Trend
  • Rising Investment in Research and Development Initiatives

Market Drivers
  • Rising Number of Cases Regarding Hypogonadism in Adult Men across the Globe
  • High Growth in Testosterone Replacement Therapy

Opportunities
  • High Adoption of the Testosterone Products in the United States Market

Restraints
  • Stringent Regulations across the Globe Majorly By the United States Food and Drugs Administration In Terms Of the Application of Testosterone Products
  • Rising Number of Risk Regarding Adverse Cardiovascular Events

Challenges
  • Rising Concern of Other Health Effective Risk from Consumers


Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Testosterone Cypionate Manufacturers, Suppliers and Distributors, Raw Material Suppliers, Government Regulatory and Research Organizations and End-Use Industries

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase

Report Objectives / Segmentation Covered

By Application
  • Primary Hypogonadism
  • Hypogonadotropic Hypogonadism
  • Late-Onset Hypogonadism
By Route of Administration
  • Injectable
  • Parenteral

By Active Ingredient
  • Testosterone
  • Methyl Testosterone
  • Testosterone Undecanoate
  • Testosterone Enanthate
  • Testosterone Cypionate

By Dose
  • 200 mg/mL
  • 100 mg/mL

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Number of Cases Regarding Hypogonadism in Adult Men across the Globe
      • 3.2.2. High Growth in Testosterone Replacement Therapy
    • 3.3. Market Challenges
      • 3.3.1. Rising Concern of Other Health Effective Risk from Consumers
    • 3.4. Market Trends
      • 3.4.1. Rising Investment in Research and Development Initiatives
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Testosterone Cypionate, by Application, Route of Administration, Active Ingredient, Dose and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Testosterone Cypionate (Value)
      • 5.2.1. Global Testosterone Cypionate by: Application (Value)
        • 5.2.1.1. Primary Hypogonadism
        • 5.2.1.2. Hypogonadotropic Hypogonadism
        • 5.2.1.3. Late-Onset Hypogonadism
      • 5.2.2. Global Testosterone Cypionate by: Route of Administration (Value)
        • 5.2.2.1. Injectable
        • 5.2.2.2. Parenteral
      • 5.2.3. Global Testosterone Cypionate by: Active Ingredient (Value)
        • 5.2.3.1. Testosterone
        • 5.2.3.2. Methyl Testosterone
        • 5.2.3.3. Testosterone Undecanoate
        • 5.2.3.4. Testosterone Enanthate
        • 5.2.3.5. Testosterone Cypionate
      • 5.2.4. Global Testosterone Cypionate by: Dose (Value)
        • 5.2.4.1. 200 mg/mL
        • 5.2.4.2. 100 mg/mL
      • 5.2.5. Global Testosterone Cypionate Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Testosterone Cypionate (Volume)
      • 5.3.1. Global Testosterone Cypionate by: Application (Volume)
        • 5.3.1.1. Primary Hypogonadism
        • 5.3.1.2. Hypogonadotropic Hypogonadism
        • 5.3.1.3. Late-Onset Hypogonadism
      • 5.3.2. Global Testosterone Cypionate by: Route of Administration (Volume)
        • 5.3.2.1. Injectable
        • 5.3.2.2. Parenteral
      • 5.3.3. Global Testosterone Cypionate by: Active Ingredient (Volume)
        • 5.3.3.1. Testosterone
        • 5.3.3.2. Methyl Testosterone
        • 5.3.3.3. Testosterone Undecanoate
        • 5.3.3.4. Testosterone Enanthate
        • 5.3.3.5. Testosterone Cypionate
      • 5.3.4. Global Testosterone Cypionate by: Dose (Volume)
        • 5.3.4.1. 200 mg/mL
        • 5.3.4.2. 100 mg/mL
      • 5.3.5. Global Testosterone Cypionate Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Testosterone Cypionate (Price)
  • 6. Testosterone Cypionate: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Cipla (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sun Pharmaceutical (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Teva (Israel)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Perrigo (Ireland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Hikma Pharmaceuticals (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Actiza Pharmaceutical Private Limited (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Abbvie, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. McKesson Corporation (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Perrigo Company plc (Ireland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Testosterone Cypionate Sale, by Application, Route of Administration, Active Ingredient, Dose and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Testosterone Cypionate (Value)
      • 7.2.1. Global Testosterone Cypionate by: Application (Value)
        • 7.2.1.1. Primary Hypogonadism
        • 7.2.1.2. Hypogonadotropic Hypogonadism
        • 7.2.1.3. Late-Onset Hypogonadism
      • 7.2.2. Global Testosterone Cypionate by: Route of Administration (Value)
        • 7.2.2.1. Injectable
        • 7.2.2.2. Parenteral
      • 7.2.3. Global Testosterone Cypionate by: Active Ingredient (Value)
        • 7.2.3.1. Testosterone
        • 7.2.3.2. Methyl Testosterone
        • 7.2.3.3. Testosterone Undecanoate
        • 7.2.3.4. Testosterone Enanthate
        • 7.2.3.5. Testosterone Cypionate
      • 7.2.4. Global Testosterone Cypionate by: Dose (Value)
        • 7.2.4.1. 200 mg/mL
        • 7.2.4.2. 100 mg/mL
      • 7.2.5. Global Testosterone Cypionate Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Testosterone Cypionate (Volume)
      • 7.3.1. Global Testosterone Cypionate by: Application (Volume)
        • 7.3.1.1. Primary Hypogonadism
        • 7.3.1.2. Hypogonadotropic Hypogonadism
        • 7.3.1.3. Late-Onset Hypogonadism
      • 7.3.2. Global Testosterone Cypionate by: Route of Administration (Volume)
        • 7.3.2.1. Injectable
        • 7.3.2.2. Parenteral
      • 7.3.3. Global Testosterone Cypionate by: Active Ingredient (Volume)
        • 7.3.3.1. Testosterone
        • 7.3.3.2. Methyl Testosterone
        • 7.3.3.3. Testosterone Undecanoate
        • 7.3.3.4. Testosterone Enanthate
        • 7.3.3.5. Testosterone Cypionate
      • 7.3.4. Global Testosterone Cypionate by: Dose (Volume)
        • 7.3.4.1. 200 mg/mL
        • 7.3.4.2. 100 mg/mL
      • 7.3.5. Global Testosterone Cypionate Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Testosterone Cypionate (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Testosterone Cypionate: by Application(USD Million)
  • Table 2. Testosterone Cypionate Primary Hypogonadism , by Region USD Million (2013-2018)
  • Table 3. Testosterone Cypionate Hypogonadotropic Hypogonadism , by Region USD Million (2013-2018)
  • Table 4. Testosterone Cypionate Late-Onset Hypogonadism , by Region USD Million (2013-2018)
  • Table 5. Testosterone Cypionate: by Route of Administration(USD Million)
  • Table 6. Testosterone Cypionate Injectable , by Region USD Million (2013-2018)
  • Table 7. Testosterone Cypionate Parenteral , by Region USD Million (2013-2018)
  • Table 8. Testosterone Cypionate: by Active Ingredient(USD Million)
  • Table 9. Testosterone Cypionate Testosterone , by Region USD Million (2013-2018)
  • Table 10. Testosterone Cypionate Methyl Testosterone , by Region USD Million (2013-2018)
  • Table 11. Testosterone Cypionate Testosterone Undecanoate , by Region USD Million (2013-2018)
  • Table 12. Testosterone Cypionate Testosterone Enanthate , by Region USD Million (2013-2018)
  • Table 13. Testosterone Cypionate Testosterone Cypionate , by Region USD Million (2013-2018)
  • Table 14. Testosterone Cypionate: by Dose(USD Million)
  • Table 15. Testosterone Cypionate 200 mg/mL , by Region USD Million (2013-2018)
  • Table 16. Testosterone Cypionate 100 mg/mL , by Region USD Million (2013-2018)
  • Table 17. South America Testosterone Cypionate, by Country USD Million (2013-2018)
  • Table 18. South America Testosterone Cypionate, by Application USD Million (2013-2018)
  • Table 19. South America Testosterone Cypionate, by Route of Administration USD Million (2013-2018)
  • Table 20. South America Testosterone Cypionate, by Active Ingredient USD Million (2013-2018)
  • Table 21. South America Testosterone Cypionate, by Dose USD Million (2013-2018)
  • Table 22. Brazil Testosterone Cypionate, by Application USD Million (2013-2018)
  • Table 23. Brazil Testosterone Cypionate, by Route of Administration USD Million (2013-2018)
  • Table 24. Brazil Testosterone Cypionate, by Active Ingredient USD Million (2013-2018)
  • Table 25. Brazil Testosterone Cypionate, by Dose USD Million (2013-2018)
  • Table 26. Argentina Testosterone Cypionate, by Application USD Million (2013-2018)
  • Table 27. Argentina Testosterone Cypionate, by Route of Administration USD Million (2013-2018)
  • Table 28. Argentina Testosterone Cypionate, by Active Ingredient USD Million (2013-2018)
  • Table 29. Argentina Testosterone Cypionate, by Dose USD Million (2013-2018)
  • Table 30. Rest of South America Testosterone Cypionate, by Application USD Million (2013-2018)
  • Table 31. Rest of South America Testosterone Cypionate, by Route of Administration USD Million (2013-2018)
  • Table 32. Rest of South America Testosterone Cypionate, by Active Ingredient USD Million (2013-2018)
  • Table 33. Rest of South America Testosterone Cypionate, by Dose USD Million (2013-2018)
  • Table 34. Asia Pacific Testosterone Cypionate, by Country USD Million (2013-2018)
  • Table 35. Asia Pacific Testosterone Cypionate, by Application USD Million (2013-2018)
  • Table 36. Asia Pacific Testosterone Cypionate, by Route of Administration USD Million (2013-2018)
  • Table 37. Asia Pacific Testosterone Cypionate, by Active Ingredient USD Million (2013-2018)
  • Table 38. Asia Pacific Testosterone Cypionate, by Dose USD Million (2013-2018)
  • Table 39. China Testosterone Cypionate, by Application USD Million (2013-2018)
  • Table 40. China Testosterone Cypionate, by Route of Administration USD Million (2013-2018)
  • Table 41. China Testosterone Cypionate, by Active Ingredient USD Million (2013-2018)
  • Table 42. China Testosterone Cypionate, by Dose USD Million (2013-2018)
  • Table 43. Japan Testosterone Cypionate, by Application USD Million (2013-2018)
  • Table 44. Japan Testosterone Cypionate, by Route of Administration USD Million (2013-2018)
  • Table 45. Japan Testosterone Cypionate, by Active Ingredient USD Million (2013-2018)
  • Table 46. Japan Testosterone Cypionate, by Dose USD Million (2013-2018)
  • Table 47. India Testosterone Cypionate, by Application USD Million (2013-2018)
  • Table 48. India Testosterone Cypionate, by Route of Administration USD Million (2013-2018)
  • Table 49. India Testosterone Cypionate, by Active Ingredient USD Million (2013-2018)
  • Table 50. India Testosterone Cypionate, by Dose USD Million (2013-2018)
  • Table 51. South Korea Testosterone Cypionate, by Application USD Million (2013-2018)
  • Table 52. South Korea Testosterone Cypionate, by Route of Administration USD Million (2013-2018)
  • Table 53. South Korea Testosterone Cypionate, by Active Ingredient USD Million (2013-2018)
  • Table 54. South Korea Testosterone Cypionate, by Dose USD Million (2013-2018)
  • Table 55. Taiwan Testosterone Cypionate, by Application USD Million (2013-2018)
  • Table 56. Taiwan Testosterone Cypionate, by Route of Administration USD Million (2013-2018)
  • Table 57. Taiwan Testosterone Cypionate, by Active Ingredient USD Million (2013-2018)
  • Table 58. Taiwan Testosterone Cypionate, by Dose USD Million (2013-2018)
  • Table 59. Australia Testosterone Cypionate, by Application USD Million (2013-2018)
  • Table 60. Australia Testosterone Cypionate, by Route of Administration USD Million (2013-2018)
  • Table 61. Australia Testosterone Cypionate, by Active Ingredient USD Million (2013-2018)
  • Table 62. Australia Testosterone Cypionate, by Dose USD Million (2013-2018)
  • Table 63. Rest of Asia-Pacific Testosterone Cypionate, by Application USD Million (2013-2018)
  • Table 64. Rest of Asia-Pacific Testosterone Cypionate, by Route of Administration USD Million (2013-2018)
  • Table 65. Rest of Asia-Pacific Testosterone Cypionate, by Active Ingredient USD Million (2013-2018)
  • Table 66. Rest of Asia-Pacific Testosterone Cypionate, by Dose USD Million (2013-2018)
  • Table 67. Europe Testosterone Cypionate, by Country USD Million (2013-2018)
  • Table 68. Europe Testosterone Cypionate, by Application USD Million (2013-2018)
  • Table 69. Europe Testosterone Cypionate, by Route of Administration USD Million (2013-2018)
  • Table 70. Europe Testosterone Cypionate, by Active Ingredient USD Million (2013-2018)
  • Table 71. Europe Testosterone Cypionate, by Dose USD Million (2013-2018)
  • Table 72. Germany Testosterone Cypionate, by Application USD Million (2013-2018)
  • Table 73. Germany Testosterone Cypionate, by Route of Administration USD Million (2013-2018)
  • Table 74. Germany Testosterone Cypionate, by Active Ingredient USD Million (2013-2018)
  • Table 75. Germany Testosterone Cypionate, by Dose USD Million (2013-2018)
  • Table 76. France Testosterone Cypionate, by Application USD Million (2013-2018)
  • Table 77. France Testosterone Cypionate, by Route of Administration USD Million (2013-2018)
  • Table 78. France Testosterone Cypionate, by Active Ingredient USD Million (2013-2018)
  • Table 79. France Testosterone Cypionate, by Dose USD Million (2013-2018)
  • Table 80. Italy Testosterone Cypionate, by Application USD Million (2013-2018)
  • Table 81. Italy Testosterone Cypionate, by Route of Administration USD Million (2013-2018)
  • Table 82. Italy Testosterone Cypionate, by Active Ingredient USD Million (2013-2018)
  • Table 83. Italy Testosterone Cypionate, by Dose USD Million (2013-2018)
  • Table 84. United Kingdom Testosterone Cypionate, by Application USD Million (2013-2018)
  • Table 85. United Kingdom Testosterone Cypionate, by Route of Administration USD Million (2013-2018)
  • Table 86. United Kingdom Testosterone Cypionate, by Active Ingredient USD Million (2013-2018)
  • Table 87. United Kingdom Testosterone Cypionate, by Dose USD Million (2013-2018)
  • Table 88. Netherlands Testosterone Cypionate, by Application USD Million (2013-2018)
  • Table 89. Netherlands Testosterone Cypionate, by Route of Administration USD Million (2013-2018)
  • Table 90. Netherlands Testosterone Cypionate, by Active Ingredient USD Million (2013-2018)
  • Table 91. Netherlands Testosterone Cypionate, by Dose USD Million (2013-2018)
  • Table 92. Rest of Europe Testosterone Cypionate, by Application USD Million (2013-2018)
  • Table 93. Rest of Europe Testosterone Cypionate, by Route of Administration USD Million (2013-2018)
  • Table 94. Rest of Europe Testosterone Cypionate, by Active Ingredient USD Million (2013-2018)
  • Table 95. Rest of Europe Testosterone Cypionate, by Dose USD Million (2013-2018)
  • Table 96. MEA Testosterone Cypionate, by Country USD Million (2013-2018)
  • Table 97. MEA Testosterone Cypionate, by Application USD Million (2013-2018)
  • Table 98. MEA Testosterone Cypionate, by Route of Administration USD Million (2013-2018)
  • Table 99. MEA Testosterone Cypionate, by Active Ingredient USD Million (2013-2018)
  • Table 100. MEA Testosterone Cypionate, by Dose USD Million (2013-2018)
  • Table 101. Middle East Testosterone Cypionate, by Application USD Million (2013-2018)
  • Table 102. Middle East Testosterone Cypionate, by Route of Administration USD Million (2013-2018)
  • Table 103. Middle East Testosterone Cypionate, by Active Ingredient USD Million (2013-2018)
  • Table 104. Middle East Testosterone Cypionate, by Dose USD Million (2013-2018)
  • Table 105. Africa Testosterone Cypionate, by Application USD Million (2013-2018)
  • Table 106. Africa Testosterone Cypionate, by Route of Administration USD Million (2013-2018)
  • Table 107. Africa Testosterone Cypionate, by Active Ingredient USD Million (2013-2018)
  • Table 108. Africa Testosterone Cypionate, by Dose USD Million (2013-2018)
  • Table 109. North America Testosterone Cypionate, by Country USD Million (2013-2018)
  • Table 110. North America Testosterone Cypionate, by Application USD Million (2013-2018)
  • Table 111. North America Testosterone Cypionate, by Route of Administration USD Million (2013-2018)
  • Table 112. North America Testosterone Cypionate, by Active Ingredient USD Million (2013-2018)
  • Table 113. North America Testosterone Cypionate, by Dose USD Million (2013-2018)
  • Table 114. United States Testosterone Cypionate, by Application USD Million (2013-2018)
  • Table 115. United States Testosterone Cypionate, by Route of Administration USD Million (2013-2018)
  • Table 116. United States Testosterone Cypionate, by Active Ingredient USD Million (2013-2018)
  • Table 117. United States Testosterone Cypionate, by Dose USD Million (2013-2018)
  • Table 118. Canada Testosterone Cypionate, by Application USD Million (2013-2018)
  • Table 119. Canada Testosterone Cypionate, by Route of Administration USD Million (2013-2018)
  • Table 120. Canada Testosterone Cypionate, by Active Ingredient USD Million (2013-2018)
  • Table 121. Canada Testosterone Cypionate, by Dose USD Million (2013-2018)
  • Table 122. Mexico Testosterone Cypionate, by Application USD Million (2013-2018)
  • Table 123. Mexico Testosterone Cypionate, by Route of Administration USD Million (2013-2018)
  • Table 124. Mexico Testosterone Cypionate, by Active Ingredient USD Million (2013-2018)
  • Table 125. Mexico Testosterone Cypionate, by Dose USD Million (2013-2018)
  • Table 126. Testosterone Cypionate Sales: by Application(K Units)
  • Table 127. Testosterone Cypionate Sales Primary Hypogonadism , by Region K Units (2013-2018)
  • Table 128. Testosterone Cypionate Sales Hypogonadotropic Hypogonadism , by Region K Units (2013-2018)
  • Table 129. Testosterone Cypionate Sales Late-Onset Hypogonadism , by Region K Units (2013-2018)
  • Table 130. Testosterone Cypionate Sales: by Route of Administration(K Units)
  • Table 131. Testosterone Cypionate Sales Injectable , by Region K Units (2013-2018)
  • Table 132. Testosterone Cypionate Sales Parenteral , by Region K Units (2013-2018)
  • Table 133. Testosterone Cypionate Sales: by Active Ingredient(K Units)
  • Table 134. Testosterone Cypionate Sales Testosterone , by Region K Units (2013-2018)
  • Table 135. Testosterone Cypionate Sales Methyl Testosterone , by Region K Units (2013-2018)
  • Table 136. Testosterone Cypionate Sales Testosterone Undecanoate , by Region K Units (2013-2018)
  • Table 137. Testosterone Cypionate Sales Testosterone Enanthate , by Region K Units (2013-2018)
  • Table 138. Testosterone Cypionate Sales Testosterone Cypionate , by Region K Units (2013-2018)
  • Table 139. Testosterone Cypionate Sales: by Dose(K Units)
  • Table 140. Testosterone Cypionate Sales 200 mg/mL , by Region K Units (2013-2018)
  • Table 141. Testosterone Cypionate Sales 100 mg/mL , by Region K Units (2013-2018)
  • Table 142. South America Testosterone Cypionate Sales, by Country K Units (2013-2018)
  • Table 143. South America Testosterone Cypionate Sales, by Application K Units (2013-2018)
  • Table 144. South America Testosterone Cypionate Sales, by Route of Administration K Units (2013-2018)
  • Table 145. South America Testosterone Cypionate Sales, by Active Ingredient K Units (2013-2018)
  • Table 146. South America Testosterone Cypionate Sales, by Dose K Units (2013-2018)
  • Table 147. Brazil Testosterone Cypionate Sales, by Application K Units (2013-2018)
  • Table 148. Brazil Testosterone Cypionate Sales, by Route of Administration K Units (2013-2018)
  • Table 149. Brazil Testosterone Cypionate Sales, by Active Ingredient K Units (2013-2018)
  • Table 150. Brazil Testosterone Cypionate Sales, by Dose K Units (2013-2018)
  • Table 151. Argentina Testosterone Cypionate Sales, by Application K Units (2013-2018)
  • Table 152. Argentina Testosterone Cypionate Sales, by Route of Administration K Units (2013-2018)
  • Table 153. Argentina Testosterone Cypionate Sales, by Active Ingredient K Units (2013-2018)
  • Table 154. Argentina Testosterone Cypionate Sales, by Dose K Units (2013-2018)
  • Table 155. Rest of South America Testosterone Cypionate Sales, by Application K Units (2013-2018)
  • Table 156. Rest of South America Testosterone Cypionate Sales, by Route of Administration K Units (2013-2018)
  • Table 157. Rest of South America Testosterone Cypionate Sales, by Active Ingredient K Units (2013-2018)
  • Table 158. Rest of South America Testosterone Cypionate Sales, by Dose K Units (2013-2018)
  • Table 159. Asia Pacific Testosterone Cypionate Sales, by Country K Units (2013-2018)
  • Table 160. Asia Pacific Testosterone Cypionate Sales, by Application K Units (2013-2018)
  • Table 161. Asia Pacific Testosterone Cypionate Sales, by Route of Administration K Units (2013-2018)
  • Table 162. Asia Pacific Testosterone Cypionate Sales, by Active Ingredient K Units (2013-2018)
  • Table 163. Asia Pacific Testosterone Cypionate Sales, by Dose K Units (2013-2018)
  • Table 164. China Testosterone Cypionate Sales, by Application K Units (2013-2018)
  • Table 165. China Testosterone Cypionate Sales, by Route of Administration K Units (2013-2018)
  • Table 166. China Testosterone Cypionate Sales, by Active Ingredient K Units (2013-2018)
  • Table 167. China Testosterone Cypionate Sales, by Dose K Units (2013-2018)
  • Table 168. Japan Testosterone Cypionate Sales, by Application K Units (2013-2018)
  • Table 169. Japan Testosterone Cypionate Sales, by Route of Administration K Units (2013-2018)
  • Table 170. Japan Testosterone Cypionate Sales, by Active Ingredient K Units (2013-2018)
  • Table 171. Japan Testosterone Cypionate Sales, by Dose K Units (2013-2018)
  • Table 172. India Testosterone Cypionate Sales, by Application K Units (2013-2018)
  • Table 173. India Testosterone Cypionate Sales, by Route of Administration K Units (2013-2018)
  • Table 174. India Testosterone Cypionate Sales, by Active Ingredient K Units (2013-2018)
  • Table 175. India Testosterone Cypionate Sales, by Dose K Units (2013-2018)
  • Table 176. South Korea Testosterone Cypionate Sales, by Application K Units (2013-2018)
  • Table 177. South Korea Testosterone Cypionate Sales, by Route of Administration K Units (2013-2018)
  • Table 178. South Korea Testosterone Cypionate Sales, by Active Ingredient K Units (2013-2018)
  • Table 179. South Korea Testosterone Cypionate Sales, by Dose K Units (2013-2018)
  • Table 180. Taiwan Testosterone Cypionate Sales, by Application K Units (2013-2018)
  • Table 181. Taiwan Testosterone Cypionate Sales, by Route of Administration K Units (2013-2018)
  • Table 182. Taiwan Testosterone Cypionate Sales, by Active Ingredient K Units (2013-2018)
  • Table 183. Taiwan Testosterone Cypionate Sales, by Dose K Units (2013-2018)
  • Table 184. Australia Testosterone Cypionate Sales, by Application K Units (2013-2018)
  • Table 185. Australia Testosterone Cypionate Sales, by Route of Administration K Units (2013-2018)
  • Table 186. Australia Testosterone Cypionate Sales, by Active Ingredient K Units (2013-2018)
  • Table 187. Australia Testosterone Cypionate Sales, by Dose K Units (2013-2018)
  • Table 188. Rest of Asia-Pacific Testosterone Cypionate Sales, by Application K Units (2013-2018)
  • Table 189. Rest of Asia-Pacific Testosterone Cypionate Sales, by Route of Administration K Units (2013-2018)
  • Table 190. Rest of Asia-Pacific Testosterone Cypionate Sales, by Active Ingredient K Units (2013-2018)
  • Table 191. Rest of Asia-Pacific Testosterone Cypionate Sales, by Dose K Units (2013-2018)
  • Table 192. Europe Testosterone Cypionate Sales, by Country K Units (2013-2018)
  • Table 193. Europe Testosterone Cypionate Sales, by Application K Units (2013-2018)
  • Table 194. Europe Testosterone Cypionate Sales, by Route of Administration K Units (2013-2018)
  • Table 195. Europe Testosterone Cypionate Sales, by Active Ingredient K Units (2013-2018)
  • Table 196. Europe Testosterone Cypionate Sales, by Dose K Units (2013-2018)
  • Table 197. Germany Testosterone Cypionate Sales, by Application K Units (2013-2018)
  • Table 198. Germany Testosterone Cypionate Sales, by Route of Administration K Units (2013-2018)
  • Table 199. Germany Testosterone Cypionate Sales, by Active Ingredient K Units (2013-2018)
  • Table 200. Germany Testosterone Cypionate Sales, by Dose K Units (2013-2018)
  • Table 201. France Testosterone Cypionate Sales, by Application K Units (2013-2018)
  • Table 202. France Testosterone Cypionate Sales, by Route of Administration K Units (2013-2018)
  • Table 203. France Testosterone Cypionate Sales, by Active Ingredient K Units (2013-2018)
  • Table 204. France Testosterone Cypionate Sales, by Dose K Units (2013-2018)
  • Table 205. Italy Testosterone Cypionate Sales, by Application K Units (2013-2018)
  • Table 206. Italy Testosterone Cypionate Sales, by Route of Administration K Units (2013-2018)
  • Table 207. Italy Testosterone Cypionate Sales, by Active Ingredient K Units (2013-2018)
  • Table 208. Italy Testosterone Cypionate Sales, by Dose K Units (2013-2018)
  • Table 209. United Kingdom Testosterone Cypionate Sales, by Application K Units (2013-2018)
  • Table 210. United Kingdom Testosterone Cypionate Sales, by Route of Administration K Units (2013-2018)
  • Table 211. United Kingdom Testosterone Cypionate Sales, by Active Ingredient K Units (2013-2018)
  • Table 212. United Kingdom Testosterone Cypionate Sales, by Dose K Units (2013-2018)
  • Table 213. Netherlands Testosterone Cypionate Sales, by Application K Units (2013-2018)
  • Table 214. Netherlands Testosterone Cypionate Sales, by Route of Administration K Units (2013-2018)
  • Table 215. Netherlands Testosterone Cypionate Sales, by Active Ingredient K Units (2013-2018)
  • Table 216. Netherlands Testosterone Cypionate Sales, by Dose K Units (2013-2018)
  • Table 217. Rest of Europe Testosterone Cypionate Sales, by Application K Units (2013-2018)
  • Table 218. Rest of Europe Testosterone Cypionate Sales, by Route of Administration K Units (2013-2018)
  • Table 219. Rest of Europe Testosterone Cypionate Sales, by Active Ingredient K Units (2013-2018)
  • Table 220. Rest of Europe Testosterone Cypionate Sales, by Dose K Units (2013-2018)
  • Table 221. MEA Testosterone Cypionate Sales, by Country K Units (2013-2018)
  • Table 222. MEA Testosterone Cypionate Sales, by Application K Units (2013-2018)
  • Table 223. MEA Testosterone Cypionate Sales, by Route of Administration K Units (2013-2018)
  • Table 224. MEA Testosterone Cypionate Sales, by Active Ingredient K Units (2013-2018)
  • Table 225. MEA Testosterone Cypionate Sales, by Dose K Units (2013-2018)
  • Table 226. Middle East Testosterone Cypionate Sales, by Application K Units (2013-2018)
  • Table 227. Middle East Testosterone Cypionate Sales, by Route of Administration K Units (2013-2018)
  • Table 228. Middle East Testosterone Cypionate Sales, by Active Ingredient K Units (2013-2018)
  • Table 229. Middle East Testosterone Cypionate Sales, by Dose K Units (2013-2018)
  • Table 230. Africa Testosterone Cypionate Sales, by Application K Units (2013-2018)
  • Table 231. Africa Testosterone Cypionate Sales, by Route of Administration K Units (2013-2018)
  • Table 232. Africa Testosterone Cypionate Sales, by Active Ingredient K Units (2013-2018)
  • Table 233. Africa Testosterone Cypionate Sales, by Dose K Units (2013-2018)
  • Table 234. North America Testosterone Cypionate Sales, by Country K Units (2013-2018)
  • Table 235. North America Testosterone Cypionate Sales, by Application K Units (2013-2018)
  • Table 236. North America Testosterone Cypionate Sales, by Route of Administration K Units (2013-2018)
  • Table 237. North America Testosterone Cypionate Sales, by Active Ingredient K Units (2013-2018)
  • Table 238. North America Testosterone Cypionate Sales, by Dose K Units (2013-2018)
  • Table 239. United States Testosterone Cypionate Sales, by Application K Units (2013-2018)
  • Table 240. United States Testosterone Cypionate Sales, by Route of Administration K Units (2013-2018)
  • Table 241. United States Testosterone Cypionate Sales, by Active Ingredient K Units (2013-2018)
  • Table 242. United States Testosterone Cypionate Sales, by Dose K Units (2013-2018)
  • Table 243. Canada Testosterone Cypionate Sales, by Application K Units (2013-2018)
  • Table 244. Canada Testosterone Cypionate Sales, by Route of Administration K Units (2013-2018)
  • Table 245. Canada Testosterone Cypionate Sales, by Active Ingredient K Units (2013-2018)
  • Table 246. Canada Testosterone Cypionate Sales, by Dose K Units (2013-2018)
  • Table 247. Mexico Testosterone Cypionate Sales, by Application K Units (2013-2018)
  • Table 248. Mexico Testosterone Cypionate Sales, by Route of Administration K Units (2013-2018)
  • Table 249. Mexico Testosterone Cypionate Sales, by Active Ingredient K Units (2013-2018)
  • Table 250. Mexico Testosterone Cypionate Sales, by Dose K Units (2013-2018)
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Testosterone Cypionate: by Application(USD Million)
  • Table 262. Testosterone Cypionate Primary Hypogonadism , by Region USD Million (2019-2024)
  • Table 263. Testosterone Cypionate Hypogonadotropic Hypogonadism , by Region USD Million (2019-2024)
  • Table 264. Testosterone Cypionate Late-Onset Hypogonadism , by Region USD Million (2019-2024)
  • Table 265. Testosterone Cypionate: by Route of Administration(USD Million)
  • Table 266. Testosterone Cypionate Injectable , by Region USD Million (2019-2024)
  • Table 267. Testosterone Cypionate Parenteral , by Region USD Million (2019-2024)
  • Table 268. Testosterone Cypionate: by Active Ingredient(USD Million)
  • Table 269. Testosterone Cypionate Testosterone , by Region USD Million (2019-2024)
  • Table 270. Testosterone Cypionate Methyl Testosterone , by Region USD Million (2019-2024)
  • Table 271. Testosterone Cypionate Testosterone Undecanoate , by Region USD Million (2019-2024)
  • Table 272. Testosterone Cypionate Testosterone Enanthate , by Region USD Million (2019-2024)
  • Table 273. Testosterone Cypionate Testosterone Cypionate , by Region USD Million (2019-2024)
  • Table 274. Testosterone Cypionate: by Dose(USD Million)
  • Table 275. Testosterone Cypionate 200 mg/mL , by Region USD Million (2019-2024)
  • Table 276. Testosterone Cypionate 100 mg/mL , by Region USD Million (2019-2024)
  • Table 277. South America Testosterone Cypionate, by Country USD Million (2019-2024)
  • Table 278. South America Testosterone Cypionate, by Application USD Million (2019-2024)
  • Table 279. South America Testosterone Cypionate, by Route of Administration USD Million (2019-2024)
  • Table 280. South America Testosterone Cypionate, by Active Ingredient USD Million (2019-2024)
  • Table 281. South America Testosterone Cypionate, by Dose USD Million (2019-2024)
  • Table 282. Brazil Testosterone Cypionate, by Application USD Million (2019-2024)
  • Table 283. Brazil Testosterone Cypionate, by Route of Administration USD Million (2019-2024)
  • Table 284. Brazil Testosterone Cypionate, by Active Ingredient USD Million (2019-2024)
  • Table 285. Brazil Testosterone Cypionate, by Dose USD Million (2019-2024)
  • Table 286. Argentina Testosterone Cypionate, by Application USD Million (2019-2024)
  • Table 287. Argentina Testosterone Cypionate, by Route of Administration USD Million (2019-2024)
  • Table 288. Argentina Testosterone Cypionate, by Active Ingredient USD Million (2019-2024)
  • Table 289. Argentina Testosterone Cypionate, by Dose USD Million (2019-2024)
  • Table 290. Rest of South America Testosterone Cypionate, by Application USD Million (2019-2024)
  • Table 291. Rest of South America Testosterone Cypionate, by Route of Administration USD Million (2019-2024)
  • Table 292. Rest of South America Testosterone Cypionate, by Active Ingredient USD Million (2019-2024)
  • Table 293. Rest of South America Testosterone Cypionate, by Dose USD Million (2019-2024)
  • Table 294. Asia Pacific Testosterone Cypionate, by Country USD Million (2019-2024)
  • Table 295. Asia Pacific Testosterone Cypionate, by Application USD Million (2019-2024)
  • Table 296. Asia Pacific Testosterone Cypionate, by Route of Administration USD Million (2019-2024)
  • Table 297. Asia Pacific Testosterone Cypionate, by Active Ingredient USD Million (2019-2024)
  • Table 298. Asia Pacific Testosterone Cypionate, by Dose USD Million (2019-2024)
  • Table 299. China Testosterone Cypionate, by Application USD Million (2019-2024)
  • Table 300. China Testosterone Cypionate, by Route of Administration USD Million (2019-2024)
  • Table 301. China Testosterone Cypionate, by Active Ingredient USD Million (2019-2024)
  • Table 302. China Testosterone Cypionate, by Dose USD Million (2019-2024)
  • Table 303. Japan Testosterone Cypionate, by Application USD Million (2019-2024)
  • Table 304. Japan Testosterone Cypionate, by Route of Administration USD Million (2019-2024)
  • Table 305. Japan Testosterone Cypionate, by Active Ingredient USD Million (2019-2024)
  • Table 306. Japan Testosterone Cypionate, by Dose USD Million (2019-2024)
  • Table 307. India Testosterone Cypionate, by Application USD Million (2019-2024)
  • Table 308. India Testosterone Cypionate, by Route of Administration USD Million (2019-2024)
  • Table 309. India Testosterone Cypionate, by Active Ingredient USD Million (2019-2024)
  • Table 310. India Testosterone Cypionate, by Dose USD Million (2019-2024)
  • Table 311. South Korea Testosterone Cypionate, by Application USD Million (2019-2024)
  • Table 312. South Korea Testosterone Cypionate, by Route of Administration USD Million (2019-2024)
  • Table 313. South Korea Testosterone Cypionate, by Active Ingredient USD Million (2019-2024)
  • Table 314. South Korea Testosterone Cypionate, by Dose USD Million (2019-2024)
  • Table 315. Taiwan Testosterone Cypionate, by Application USD Million (2019-2024)
  • Table 316. Taiwan Testosterone Cypionate, by Route of Administration USD Million (2019-2024)
  • Table 317. Taiwan Testosterone Cypionate, by Active Ingredient USD Million (2019-2024)
  • Table 318. Taiwan Testosterone Cypionate, by Dose USD Million (2019-2024)
  • Table 319. Australia Testosterone Cypionate, by Application USD Million (2019-2024)
  • Table 320. Australia Testosterone Cypionate, by Route of Administration USD Million (2019-2024)
  • Table 321. Australia Testosterone Cypionate, by Active Ingredient USD Million (2019-2024)
  • Table 322. Australia Testosterone Cypionate, by Dose USD Million (2019-2024)
  • Table 323. Rest of Asia-Pacific Testosterone Cypionate, by Application USD Million (2019-2024)
  • Table 324. Rest of Asia-Pacific Testosterone Cypionate, by Route of Administration USD Million (2019-2024)
  • Table 325. Rest of Asia-Pacific Testosterone Cypionate, by Active Ingredient USD Million (2019-2024)
  • Table 326. Rest of Asia-Pacific Testosterone Cypionate, by Dose USD Million (2019-2024)
  • Table 327. Europe Testosterone Cypionate, by Country USD Million (2019-2024)
  • Table 328. Europe Testosterone Cypionate, by Application USD Million (2019-2024)
  • Table 329. Europe Testosterone Cypionate, by Route of Administration USD Million (2019-2024)
  • Table 330. Europe Testosterone Cypionate, by Active Ingredient USD Million (2019-2024)
  • Table 331. Europe Testosterone Cypionate, by Dose USD Million (2019-2024)
  • Table 332. Germany Testosterone Cypionate, by Application USD Million (2019-2024)
  • Table 333. Germany Testosterone Cypionate, by Route of Administration USD Million (2019-2024)
  • Table 334. Germany Testosterone Cypionate, by Active Ingredient USD Million (2019-2024)
  • Table 335. Germany Testosterone Cypionate, by Dose USD Million (2019-2024)
  • Table 336. France Testosterone Cypionate, by Application USD Million (2019-2024)
  • Table 337. France Testosterone Cypionate, by Route of Administration USD Million (2019-2024)
  • Table 338. France Testosterone Cypionate, by Active Ingredient USD Million (2019-2024)
  • Table 339. France Testosterone Cypionate, by Dose USD Million (2019-2024)
  • Table 340. Italy Testosterone Cypionate, by Application USD Million (2019-2024)
  • Table 341. Italy Testosterone Cypionate, by Route of Administration USD Million (2019-2024)
  • Table 342. Italy Testosterone Cypionate, by Active Ingredient USD Million (2019-2024)
  • Table 343. Italy Testosterone Cypionate, by Dose USD Million (2019-2024)
  • Table 344. United Kingdom Testosterone Cypionate, by Application USD Million (2019-2024)
  • Table 345. United Kingdom Testosterone Cypionate, by Route of Administration USD Million (2019-2024)
  • Table 346. United Kingdom Testosterone Cypionate, by Active Ingredient USD Million (2019-2024)
  • Table 347. United Kingdom Testosterone Cypionate, by Dose USD Million (2019-2024)
  • Table 348. Netherlands Testosterone Cypionate, by Application USD Million (2019-2024)
  • Table 349. Netherlands Testosterone Cypionate, by Route of Administration USD Million (2019-2024)
  • Table 350. Netherlands Testosterone Cypionate, by Active Ingredient USD Million (2019-2024)
  • Table 351. Netherlands Testosterone Cypionate, by Dose USD Million (2019-2024)
  • Table 352. Rest of Europe Testosterone Cypionate, by Application USD Million (2019-2024)
  • Table 353. Rest of Europe Testosterone Cypionate, by Route of Administration USD Million (2019-2024)
  • Table 354. Rest of Europe Testosterone Cypionate, by Active Ingredient USD Million (2019-2024)
  • Table 355. Rest of Europe Testosterone Cypionate, by Dose USD Million (2019-2024)
  • Table 356. MEA Testosterone Cypionate, by Country USD Million (2019-2024)
  • Table 357. MEA Testosterone Cypionate, by Application USD Million (2019-2024)
  • Table 358. MEA Testosterone Cypionate, by Route of Administration USD Million (2019-2024)
  • Table 359. MEA Testosterone Cypionate, by Active Ingredient USD Million (2019-2024)
  • Table 360. MEA Testosterone Cypionate, by Dose USD Million (2019-2024)
  • Table 361. Middle East Testosterone Cypionate, by Application USD Million (2019-2024)
  • Table 362. Middle East Testosterone Cypionate, by Route of Administration USD Million (2019-2024)
  • Table 363. Middle East Testosterone Cypionate, by Active Ingredient USD Million (2019-2024)
  • Table 364. Middle East Testosterone Cypionate, by Dose USD Million (2019-2024)
  • Table 365. Africa Testosterone Cypionate, by Application USD Million (2019-2024)
  • Table 366. Africa Testosterone Cypionate, by Route of Administration USD Million (2019-2024)
  • Table 367. Africa Testosterone Cypionate, by Active Ingredient USD Million (2019-2024)
  • Table 368. Africa Testosterone Cypionate, by Dose USD Million (2019-2024)
  • Table 369. North America Testosterone Cypionate, by Country USD Million (2019-2024)
  • Table 370. North America Testosterone Cypionate, by Application USD Million (2019-2024)
  • Table 371. North America Testosterone Cypionate, by Route of Administration USD Million (2019-2024)
  • Table 372. North America Testosterone Cypionate, by Active Ingredient USD Million (2019-2024)
  • Table 373. North America Testosterone Cypionate, by Dose USD Million (2019-2024)
  • Table 374. United States Testosterone Cypionate, by Application USD Million (2019-2024)
  • Table 375. United States Testosterone Cypionate, by Route of Administration USD Million (2019-2024)
  • Table 376. United States Testosterone Cypionate, by Active Ingredient USD Million (2019-2024)
  • Table 377. United States Testosterone Cypionate, by Dose USD Million (2019-2024)
  • Table 378. Canada Testosterone Cypionate, by Application USD Million (2019-2024)
  • Table 379. Canada Testosterone Cypionate, by Route of Administration USD Million (2019-2024)
  • Table 380. Canada Testosterone Cypionate, by Active Ingredient USD Million (2019-2024)
  • Table 381. Canada Testosterone Cypionate, by Dose USD Million (2019-2024)
  • Table 382. Mexico Testosterone Cypionate, by Application USD Million (2019-2024)
  • Table 383. Mexico Testosterone Cypionate, by Route of Administration USD Million (2019-2024)
  • Table 384. Mexico Testosterone Cypionate, by Active Ingredient USD Million (2019-2024)
  • Table 385. Mexico Testosterone Cypionate, by Dose USD Million (2019-2024)
  • Table 386. Testosterone Cypionate Sales: by Application(K Units)
  • Table 387. Testosterone Cypionate Sales Primary Hypogonadism , by Region K Units (2019-2024)
  • Table 388. Testosterone Cypionate Sales Hypogonadotropic Hypogonadism , by Region K Units (2019-2024)
  • Table 389. Testosterone Cypionate Sales Late-Onset Hypogonadism , by Region K Units (2019-2024)
  • Table 390. Testosterone Cypionate Sales: by Route of Administration(K Units)
  • Table 391. Testosterone Cypionate Sales Injectable , by Region K Units (2019-2024)
  • Table 392. Testosterone Cypionate Sales Parenteral , by Region K Units (2019-2024)
  • Table 393. Testosterone Cypionate Sales: by Active Ingredient(K Units)
  • Table 394. Testosterone Cypionate Sales Testosterone , by Region K Units (2019-2024)
  • Table 395. Testosterone Cypionate Sales Methyl Testosterone , by Region K Units (2019-2024)
  • Table 396. Testosterone Cypionate Sales Testosterone Undecanoate , by Region K Units (2019-2024)
  • Table 397. Testosterone Cypionate Sales Testosterone Enanthate , by Region K Units (2019-2024)
  • Table 398. Testosterone Cypionate Sales Testosterone Cypionate , by Region K Units (2019-2024)
  • Table 399. Testosterone Cypionate Sales: by Dose(K Units)
  • Table 400. Testosterone Cypionate Sales 200 mg/mL , by Region K Units (2019-2024)
  • Table 401. Testosterone Cypionate Sales 100 mg/mL , by Region K Units (2019-2024)
  • Table 402. South America Testosterone Cypionate Sales, by Country K Units (2019-2024)
  • Table 403. South America Testosterone Cypionate Sales, by Application K Units (2019-2024)
  • Table 404. South America Testosterone Cypionate Sales, by Route of Administration K Units (2019-2024)
  • Table 405. South America Testosterone Cypionate Sales, by Active Ingredient K Units (2019-2024)
  • Table 406. South America Testosterone Cypionate Sales, by Dose K Units (2019-2024)
  • Table 407. Brazil Testosterone Cypionate Sales, by Application K Units (2019-2024)
  • Table 408. Brazil Testosterone Cypionate Sales, by Route of Administration K Units (2019-2024)
  • Table 409. Brazil Testosterone Cypionate Sales, by Active Ingredient K Units (2019-2024)
  • Table 410. Brazil Testosterone Cypionate Sales, by Dose K Units (2019-2024)
  • Table 411. Argentina Testosterone Cypionate Sales, by Application K Units (2019-2024)
  • Table 412. Argentina Testosterone Cypionate Sales, by Route of Administration K Units (2019-2024)
  • Table 413. Argentina Testosterone Cypionate Sales, by Active Ingredient K Units (2019-2024)
  • Table 414. Argentina Testosterone Cypionate Sales, by Dose K Units (2019-2024)
  • Table 415. Rest of South America Testosterone Cypionate Sales, by Application K Units (2019-2024)
  • Table 416. Rest of South America Testosterone Cypionate Sales, by Route of Administration K Units (2019-2024)
  • Table 417. Rest of South America Testosterone Cypionate Sales, by Active Ingredient K Units (2019-2024)
  • Table 418. Rest of South America Testosterone Cypionate Sales, by Dose K Units (2019-2024)
  • Table 419. Asia Pacific Testosterone Cypionate Sales, by Country K Units (2019-2024)
  • Table 420. Asia Pacific Testosterone Cypionate Sales, by Application K Units (2019-2024)
  • Table 421. Asia Pacific Testosterone Cypionate Sales, by Route of Administration K Units (2019-2024)
  • Table 422. Asia Pacific Testosterone Cypionate Sales, by Active Ingredient K Units (2019-2024)
  • Table 423. Asia Pacific Testosterone Cypionate Sales, by Dose K Units (2019-2024)
  • Table 424. China Testosterone Cypionate Sales, by Application K Units (2019-2024)
  • Table 425. China Testosterone Cypionate Sales, by Route of Administration K Units (2019-2024)
  • Table 426. China Testosterone Cypionate Sales, by Active Ingredient K Units (2019-2024)
  • Table 427. China Testosterone Cypionate Sales, by Dose K Units (2019-2024)
  • Table 428. Japan Testosterone Cypionate Sales, by Application K Units (2019-2024)
  • Table 429. Japan Testosterone Cypionate Sales, by Route of Administration K Units (2019-2024)
  • Table 430. Japan Testosterone Cypionate Sales, by Active Ingredient K Units (2019-2024)
  • Table 431. Japan Testosterone Cypionate Sales, by Dose K Units (2019-2024)
  • Table 432. India Testosterone Cypionate Sales, by Application K Units (2019-2024)
  • Table 433. India Testosterone Cypionate Sales, by Route of Administration K Units (2019-2024)
  • Table 434. India Testosterone Cypionate Sales, by Active Ingredient K Units (2019-2024)
  • Table 435. India Testosterone Cypionate Sales, by Dose K Units (2019-2024)
  • Table 436. South Korea Testosterone Cypionate Sales, by Application K Units (2019-2024)
  • Table 437. South Korea Testosterone Cypionate Sales, by Route of Administration K Units (2019-2024)
  • Table 438. South Korea Testosterone Cypionate Sales, by Active Ingredient K Units (2019-2024)
  • Table 439. South Korea Testosterone Cypionate Sales, by Dose K Units (2019-2024)
  • Table 440. Taiwan Testosterone Cypionate Sales, by Application K Units (2019-2024)
  • Table 441. Taiwan Testosterone Cypionate Sales, by Route of Administration K Units (2019-2024)
  • Table 442. Taiwan Testosterone Cypionate Sales, by Active Ingredient K Units (2019-2024)
  • Table 443. Taiwan Testosterone Cypionate Sales, by Dose K Units (2019-2024)
  • Table 444. Australia Testosterone Cypionate Sales, by Application K Units (2019-2024)
  • Table 445. Australia Testosterone Cypionate Sales, by Route of Administration K Units (2019-2024)
  • Table 446. Australia Testosterone Cypionate Sales, by Active Ingredient K Units (2019-2024)
  • Table 447. Australia Testosterone Cypionate Sales, by Dose K Units (2019-2024)
  • Table 448. Rest of Asia-Pacific Testosterone Cypionate Sales, by Application K Units (2019-2024)
  • Table 449. Rest of Asia-Pacific Testosterone Cypionate Sales, by Route of Administration K Units (2019-2024)
  • Table 450. Rest of Asia-Pacific Testosterone Cypionate Sales, by Active Ingredient K Units (2019-2024)
  • Table 451. Rest of Asia-Pacific Testosterone Cypionate Sales, by Dose K Units (2019-2024)
  • Table 452. Europe Testosterone Cypionate Sales, by Country K Units (2019-2024)
  • Table 453. Europe Testosterone Cypionate Sales, by Application K Units (2019-2024)
  • Table 454. Europe Testosterone Cypionate Sales, by Route of Administration K Units (2019-2024)
  • Table 455. Europe Testosterone Cypionate Sales, by Active Ingredient K Units (2019-2024)
  • Table 456. Europe Testosterone Cypionate Sales, by Dose K Units (2019-2024)
  • Table 457. Germany Testosterone Cypionate Sales, by Application K Units (2019-2024)
  • Table 458. Germany Testosterone Cypionate Sales, by Route of Administration K Units (2019-2024)
  • Table 459. Germany Testosterone Cypionate Sales, by Active Ingredient K Units (2019-2024)
  • Table 460. Germany Testosterone Cypionate Sales, by Dose K Units (2019-2024)
  • Table 461. France Testosterone Cypionate Sales, by Application K Units (2019-2024)
  • Table 462. France Testosterone Cypionate Sales, by Route of Administration K Units (2019-2024)
  • Table 463. France Testosterone Cypionate Sales, by Active Ingredient K Units (2019-2024)
  • Table 464. France Testosterone Cypionate Sales, by Dose K Units (2019-2024)
  • Table 465. Italy Testosterone Cypionate Sales, by Application K Units (2019-2024)
  • Table 466. Italy Testosterone Cypionate Sales, by Route of Administration K Units (2019-2024)
  • Table 467. Italy Testosterone Cypionate Sales, by Active Ingredient K Units (2019-2024)
  • Table 468. Italy Testosterone Cypionate Sales, by Dose K Units (2019-2024)
  • Table 469. United Kingdom Testosterone Cypionate Sales, by Application K Units (2019-2024)
  • Table 470. United Kingdom Testosterone Cypionate Sales, by Route of Administration K Units (2019-2024)
  • Table 471. United Kingdom Testosterone Cypionate Sales, by Active Ingredient K Units (2019-2024)
  • Table 472. United Kingdom Testosterone Cypionate Sales, by Dose K Units (2019-2024)
  • Table 473. Netherlands Testosterone Cypionate Sales, by Application K Units (2019-2024)
  • Table 474. Netherlands Testosterone Cypionate Sales, by Route of Administration K Units (2019-2024)
  • Table 475. Netherlands Testosterone Cypionate Sales, by Active Ingredient K Units (2019-2024)
  • Table 476. Netherlands Testosterone Cypionate Sales, by Dose K Units (2019-2024)
  • Table 477. Rest of Europe Testosterone Cypionate Sales, by Application K Units (2019-2024)
  • Table 478. Rest of Europe Testosterone Cypionate Sales, by Route of Administration K Units (2019-2024)
  • Table 479. Rest of Europe Testosterone Cypionate Sales, by Active Ingredient K Units (2019-2024)
  • Table 480. Rest of Europe Testosterone Cypionate Sales, by Dose K Units (2019-2024)
  • Table 481. MEA Testosterone Cypionate Sales, by Country K Units (2019-2024)
  • Table 482. MEA Testosterone Cypionate Sales, by Application K Units (2019-2024)
  • Table 483. MEA Testosterone Cypionate Sales, by Route of Administration K Units (2019-2024)
  • Table 484. MEA Testosterone Cypionate Sales, by Active Ingredient K Units (2019-2024)
  • Table 485. MEA Testosterone Cypionate Sales, by Dose K Units (2019-2024)
  • Table 486. Middle East Testosterone Cypionate Sales, by Application K Units (2019-2024)
  • Table 487. Middle East Testosterone Cypionate Sales, by Route of Administration K Units (2019-2024)
  • Table 488. Middle East Testosterone Cypionate Sales, by Active Ingredient K Units (2019-2024)
  • Table 489. Middle East Testosterone Cypionate Sales, by Dose K Units (2019-2024)
  • Table 490. Africa Testosterone Cypionate Sales, by Application K Units (2019-2024)
  • Table 491. Africa Testosterone Cypionate Sales, by Route of Administration K Units (2019-2024)
  • Table 492. Africa Testosterone Cypionate Sales, by Active Ingredient K Units (2019-2024)
  • Table 493. Africa Testosterone Cypionate Sales, by Dose K Units (2019-2024)
  • Table 494. North America Testosterone Cypionate Sales, by Country K Units (2019-2024)
  • Table 495. North America Testosterone Cypionate Sales, by Application K Units (2019-2024)
  • Table 496. North America Testosterone Cypionate Sales, by Route of Administration K Units (2019-2024)
  • Table 497. North America Testosterone Cypionate Sales, by Active Ingredient K Units (2019-2024)
  • Table 498. North America Testosterone Cypionate Sales, by Dose K Units (2019-2024)
  • Table 499. United States Testosterone Cypionate Sales, by Application K Units (2019-2024)
  • Table 500. United States Testosterone Cypionate Sales, by Route of Administration K Units (2019-2024)
  • Table 501. United States Testosterone Cypionate Sales, by Active Ingredient K Units (2019-2024)
  • Table 502. United States Testosterone Cypionate Sales, by Dose K Units (2019-2024)
  • Table 503. Canada Testosterone Cypionate Sales, by Application K Units (2019-2024)
  • Table 504. Canada Testosterone Cypionate Sales, by Route of Administration K Units (2019-2024)
  • Table 505. Canada Testosterone Cypionate Sales, by Active Ingredient K Units (2019-2024)
  • Table 506. Canada Testosterone Cypionate Sales, by Dose K Units (2019-2024)
  • Table 507. Mexico Testosterone Cypionate Sales, by Application K Units (2019-2024)
  • Table 508. Mexico Testosterone Cypionate Sales, by Route of Administration K Units (2019-2024)
  • Table 509. Mexico Testosterone Cypionate Sales, by Active Ingredient K Units (2019-2024)
  • Table 510. Mexico Testosterone Cypionate Sales, by Dose K Units (2019-2024)
  • Table 511. Research Programs/Design for This Report
  • Table 512. Key Data Information from Secondary Sources
  • Table 513. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Testosterone Cypionate: by Application USD Million (2013-2018)
  • Figure 5. Global Testosterone Cypionate: by Route of Administration USD Million (2013-2018)
  • Figure 6. Global Testosterone Cypionate: by Active Ingredient USD Million (2013-2018)
  • Figure 7. Global Testosterone Cypionate: by Dose USD Million (2013-2018)
  • Figure 8. South America Testosterone Cypionate Share (%), by Country
  • Figure 9. Asia Pacific Testosterone Cypionate Share (%), by Country
  • Figure 10. Europe Testosterone Cypionate Share (%), by Country
  • Figure 11. MEA Testosterone Cypionate Share (%), by Country
  • Figure 12. North America Testosterone Cypionate Share (%), by Country
  • Figure 13. Global Testosterone Cypionate: by Application K Units (2013-2018)
  • Figure 14. Global Testosterone Cypionate: by Route of Administration K Units (2013-2018)
  • Figure 15. Global Testosterone Cypionate: by Active Ingredient K Units (2013-2018)
  • Figure 16. Global Testosterone Cypionate: by Dose K Units (2013-2018)
  • Figure 17. South America Testosterone Cypionate Share (%), by Country
  • Figure 18. Asia Pacific Testosterone Cypionate Share (%), by Country
  • Figure 19. Europe Testosterone Cypionate Share (%), by Country
  • Figure 20. MEA Testosterone Cypionate Share (%), by Country
  • Figure 21. North America Testosterone Cypionate Share (%), by Country
  • Figure 22. Global Testosterone Cypionate share by Players 2018 (%)
  • Figure 23. Global Testosterone Cypionate share by Players (Top 3) 2018(%)
  • Figure 24. Global Testosterone Cypionate share by Players (Top 5) 2018(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 27. Pfizer (United States) Revenue: by Geography 2018
  • Figure 28. Cipla (India) Revenue, Net Income and Gross profit
  • Figure 29. Cipla (India) Revenue: by Geography 2018
  • Figure 30. Sun Pharmaceutical (India) Revenue, Net Income and Gross profit
  • Figure 31. Sun Pharmaceutical (India) Revenue: by Geography 2018
  • Figure 32. Teva (Israel) Revenue, Net Income and Gross profit
  • Figure 33. Teva (Israel) Revenue: by Geography 2018
  • Figure 34. Perrigo (Ireland) Revenue, Net Income and Gross profit
  • Figure 35. Perrigo (Ireland) Revenue: by Geography 2018
  • Figure 36. Hikma Pharmaceuticals (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 37. Hikma Pharmaceuticals (United Kingdom) Revenue: by Geography 2018
  • Figure 38. Actiza Pharmaceutical Private Limited (India) Revenue, Net Income and Gross profit
  • Figure 39. Actiza Pharmaceutical Private Limited (India) Revenue: by Geography 2018
  • Figure 40. Abbvie, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 41. Abbvie, Inc. (United States) Revenue: by Geography 2018
  • Figure 42. McKesson Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 43. McKesson Corporation (United States) Revenue: by Geography 2018
  • Figure 44. Perrigo Company plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 45. Perrigo Company plc (Ireland) Revenue: by Geography 2018
  • Figure 46. Global Testosterone Cypionate: by Application USD Million (2019-2024)
  • Figure 47. Global Testosterone Cypionate: by Route of Administration USD Million (2019-2024)
  • Figure 48. Global Testosterone Cypionate: by Active Ingredient USD Million (2019-2024)
  • Figure 49. Global Testosterone Cypionate: by Dose USD Million (2019-2024)
  • Figure 50. South America Testosterone Cypionate Share (%), by Country
  • Figure 51. Asia Pacific Testosterone Cypionate Share (%), by Country
  • Figure 52. Europe Testosterone Cypionate Share (%), by Country
  • Figure 53. MEA Testosterone Cypionate Share (%), by Country
  • Figure 54. North America Testosterone Cypionate Share (%), by Country
  • Figure 55. Global Testosterone Cypionate: by Application K Units (2019-2024)
  • Figure 56. Global Testosterone Cypionate: by Route of Administration K Units (2019-2024)
  • Figure 57. Global Testosterone Cypionate: by Active Ingredient K Units (2019-2024)
  • Figure 58. Global Testosterone Cypionate: by Dose K Units (2019-2024)
  • Figure 59. South America Testosterone Cypionate Share (%), by Country
  • Figure 60. Asia Pacific Testosterone Cypionate Share (%), by Country
  • Figure 61. Europe Testosterone Cypionate Share (%), by Country
  • Figure 62. MEA Testosterone Cypionate Share (%), by Country
  • Figure 63. North America Testosterone Cypionate Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer (United States)
  • Cipla (India)
  • Sun Pharmaceutical (India)
  • Teva (Israel)
  • Perrigo (Ireland)
  • Hikma Pharmaceuticals (United Kingdom)
  • Actiza Pharmaceutical Private Limited (India)
  • Abbvie, Inc. (United States)
  • McKesson Corporation (United States)
  • Perrigo Company plc (Ireland)
Select User Access Type

Key Highlights of Report


Feb 2020 242 Pages 76 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Testosterone Cypionate Quantitative research analysis
Global Testosterone Cypionate Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Testosterone Cypionate Report?

Have a Query? Click Here

Other Related Reports

Central Lab Services Comprehensive Study by Type (Medical Microbiology & Cytology, Blood Bank/ Transfusion Medicine, HLA Typing, Toxicology, Andrology, Hematology, Clinical Chemistry, Endocrinology, ...
$ 3750
Ophthalmic Lenses Comprehensive Study by Type (Single-Vision Lens, Multifocal Lenses (Bifocal and Trifocal Lenses), Progressive Lenses, Light Protection Lenses (Tints, Blue Blocking Filters, Polarisi...
$ 3750
Embryonic Stem Cell Comprehensive Study by Application (Neurological Disorders, Orthopedic Treatments, Oncology Disorders, Diabetes, Injuries and Wounds, Cardiovascular Disorders, Others (Drug Develo...
$ 3450
Probiotic Comprehensive Study by Application (Food and Beverages, Dietary Supplements, Animal Feed), Strains (Animalis, Breve, Lactis (Buttermilk, Cottage cheese, other cheeses), Longum, Acidophilus,...
$ 3750
D-Ribose Comprehensive Study by Type (Food Grade D-Ribose, Pharmaceutical Grade D-Ribose), Application (Pharmaceutical Intermediate, Food Additives, Sports Supplement, Health Products), Form (Crystal...
$ 3650
Medicinal Cannabis Comprehensive Study by Type (Flowers, Concentrates, Others), Application (Hospitals, Clinics, Medical Research Centers), Distribution Channel (Dispensaries, Pharmacies, Online Reta...
$ 3650